[ACCESSWIRE]
CORAL GABLES, FL / ACCESSWIRE / March 4, 2019 / The healthcare stock market has managed to consistently garner significant amounts of attention over the course of the last few months, as more healthcare companies have focused their efforts on developing innovative care options for their patients. With headlines seeming to pop up almost every single day detailing the strides taken by companies in the healthcare sector, this has worked to attract investors looking for potential opportunities. As an industry whose success is determined by keeping consumers healthy, it is the responsibility of healthcare companies to meet the growing demands of patients in need of quality care and support. Premier Health Group (OTC: PHGRF) (CSE: PHGI), BioPharmX Corporation (BPMX), Medigus Ltd ( MDGS ), and Synergy Pharmaceuticals Inc (SGYP) represent 4 healthcare stocks heating up on Monday.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) is a company steadfast in their goal of developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to create a patient-centric healthcare framework to improve the quality of life for its patient network.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) last week announced the launch of at technology-enabled mental health counseling service for patients in urban centers and remote and underserved populations. Dr. Tahmeena Ali and Dr. Robert McKenzie are two Vancouver-based family physicians with extensive experience in mental health care and will be championing the initiative. Mental health has become something of a taboo to discuss, let alone seek treatment, and Premier is taking the steps to help their patients receive the care they need.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), commented, "it's disheartening to hear that 1 in 5 people in Canada will personally experience a mental health problem or illness and due to the lack of accessibility to care providers, we are failing to meet the needs of mental health care provision. Having the ability to offer virtual mental health counseling services is pivotal to our patient-centric app. Through my own practice, I have encountered a significant number of teens and young adults who would much rather use virtual services from the comfort of their home than come in person and wait in a busy waiting room to talk about their mental health."
For More Information On Premier Health Group, Click Here
BioPharmX Corporation (BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that the Company has completed enrollment of its Phase 2b clinical trial with BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
Following the announcement, David Tierney, CEO of BioPharmx, said, "based on results from earlier studies, we believe that BPX-04 may provide an effective treatment for rosacea while minimizing the unwanted adverse effects associated with oral forms of antibiotics, as well as the tolerability limitations of topical treatments, thereby addressing an unmet need for 16 million patients in the US alone."
For More Information On BioPharmX Corporation, Click Here
Medigus Ltd (MDGS), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, made headlines today when the Company announced that it has entered into a binding memorandum of understanding with Linkury Ltd., a wholly-owned subsidiary of Algomizer Ltd.
Per the details of the agreement, Linkury will establish a commercial technological platform for the manufacturing, marketing, and distribution of cannabidiol based CBD products. In addition, the two companies will examine entering into a definitive agreement and the formation of an international advertisement company, which will carry out the joint venture.
For More Information on Medigus Ltd, Click Here
Synergy Pharmaceuticals Inc (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, announced towards the end of last week that the previously announced agreement with Bausch Health Companies Inc. has been approved by the Bankruptcy Court.
According to the announcement, the sale of Synergy's assets, including all rights to TRULANCE® (plecanatide), dolcanatide and related intellectual property, is now expected to close on or about March 5, 2019. The Company, on December 12, 2018, initiated voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York to facilitate a sale and address its debt obligations.
For More Information On Synergy Pharmaceuticals Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to May 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
[email protected]
SOURCE: StockPrice.coms
